Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT2 | P31751 | 6/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.44 |
| ▸ | AKT1 | P31749 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.38 |
| ▸ | PARP14 | Q460N5 | 2/20 | 0.38 |
| ▸ | HTR1A | P08908 | 2/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | PTGES | O14684 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.37 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
| ▸ | DCAF15 | Q66K64 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4874896 | 0.83 | AKT2 (0.45) | AKT2GSK3BTRPV1TYMSPARP14 | |
| SCHEMBL4865960 | 0.82 | PIK3CD (0.55) | AKT2CYP2D6CYP2C9RPS6KB1AKT1 | |
| SCHEMBL16298728 | 0.76 | TERT (0.55) | PARP14LMNA | |
| SCHEMBL4869767 | 0.71 | AKT2 (0.53) | AKT2CYP2D6CYP2C9RPS6KB1AKT1 | |
| SCHEMBL6670119 | 0.70 | TYMS (0.63) | TRPV1TYMSLMNA | |
| SCHEMBL4876064 | 0.68 | AKT2 (0.44) | AKT2GSK3BLMNA | |
| SCHEMBL20509747 | 0.66 | KDM4E (0.59) | LMNA | |
| SCHEMBL4875291 | 0.66 | PIK3CD (0.58) | AKT2GSK3B | |
| SCHEMBL4869946 | 0.66 | PIK3CD (0.55) | AKT2AKT1GSK3BDCAF15 | |
| SCHEMBL8267927 | 0.65 | AKT2 (0.49) | AKT2CYP2D6CYP2C9RPS6KB1AKT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | ASTEX THERAPEUTICS LIMITED (GB) | 2008-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080275029-A1 | Compounds for Treating Protein-Kinase Mediated Disorders | CNKSR1, PRKCH, PRKAR2B | AKT2 412/4885CYP2D6 4109/4885CYP2C9 4521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.